… anticoagulant used. Recently, several other medications known as novel oral anticoagulants
(NOACs) have been studied and released on the market as alternatives to warfarin. Given …

… new oral anticoagulant and 29 272 participants received warfarin. New oral anticoagulants
significantly reduced stroke or systemic embolic events by 19% compared with warfarin (RR 0…

… oral anticoagulant’ used in this update refers to oral vitamin K antagonists (VKA), such as
warfarin… of continued LMWH over oral anticoagulant therapy with warfarin in patients with …

… The present paper describes 2 new oral anticoagulant agents, dabigatran (a direct thrombin
inhibitor) and rivaroxaban (a factor Xa inhibitor). Dabigatran and rivaroxaban are licensed in …

… warfarin is continuously expanding, and the knowledge on drug interactions with the novel
oral anticoagulants is … interactions with warfarin and the novel oral anticoagulants, dabigatran, …

… large phase III trials of novel oral anticoagulants compared to warfarin in patients with atrial
… major benefits of the novel oral anticoagulants compared to warfarin are related to a lower …

… intensity of anticoagulation, … warfarin in our trial achieved a clear reduction in IHD, particularly
fatal events, providing further evidence that conventional intensities of oral anticoagulation …

… Currently, treatment with warfarin including regular international normalized ratio monitoring
costs less than $300 per annum. The new anticoagulants examined in this study cost more …

… Outcomes of warfarin treatment depend on the quality of anticoagulation control, which …
oral anticoagulants could be used as alternatives to warfarin treatment for stroke prevention …

… in 2010, direct oral anticoagulants (DOACs) have come to replace warfarin as the preferred
… for chronic anticoagulation, including venous thromboembolism (VTE) recurrence prevention …